Humacyte Q2 2026: Breakthrough Dialysis Data, CTEV IND Accepted, $80.3M Cash

summarizeSummary

Humacyte's Q2 2026 update features breakthrough Phase 3 dialysis data, FDA acceptance of a new IND for coronary bypass grafts, and $80.3 million in cash—but also a $36.8 million quarterly loss, underscoring the race between pipeline execution and cash runway.

check_boxKey Events · Earnings and Guidance · HUMA

• Breakthrough V012 Phase 3 Dialysis Results

  The ATEV outperformed the AV fistula in female dialysis patients, meeting the primary endpoint with 91 more catheter-free days (p=0.00070). A supplemental BLA is planned for H2 2026.

• CTEV IND Accepted for CABG

  The FDA accepted the IND for a first-in-human coronary artery bypass graft study; a Phase 2a trial is expected to start in Q3 2026.

• Q2 2026 Financials: $80.3M Cash, $36.8M Loss

  Revenue was $0.4M from Symvess. The net loss of $36.8M was driven by R&D and a non-cash earnout remeasurement. Cash stood at $80.3M as of June 30, 2026, bolstered by a $57.5M June offering.

• Commercial and Surgical Leadership Appointments

  James Mercadante was appointed Chief Commercial Officer, and Dr. Todd E. Rasmussen was appointed Chief Surgical Officer to drive Symvess adoption and professional education.

auto_awesomeAnalysis · HUMA · Life Sciences

Humacyte's Q2 2026 results arrived alongside transformative pipeline progress. In the V012 Phase 3 trial for female dialysis patients, the ATEV outperformed the current standard of care—a result that could significantly expand the addressable market if the planned sBLA is approved. Meanwhile, the FDA accepted the IND for the CTEV in CABG, opening a new multibillion-dollar opportunity. Financially, the company holds $80.3 million in cash after a $57.5 million June offering, but continues to burn cash with a $36.8 million quarterly net loss. The combination of clinical breakthroughs and a fragile balance sheet makes this a high-stakes update.